Wednesday, July 14. 2010 Congress Sessions cont’d Wednesday, July 14, 2010 PLENARY SESSIONS 08:45 – 10: 15 Plenary 07≤ Room: Buenos Aires Chair: Susana Meschengieser, Argent<strong>in</strong>a Women & Bleed<strong>in</strong>g Disorders Andra James, U.S.A. Plenary 08≤ Room: Buenos Aires Chair: Raúl Pérez-Bianco, Argent<strong>in</strong>a Prophylaxis Victor Blanchette, Canada 10:15 – 10:45 REFRESHMENT BREAK 10:45 – 12:15 CONCURRENT SESSIONS W1.1 - MEDICAL≤ Cl<strong>in</strong>ical Issues <strong>in</strong> Inhibitors Room: Buenos Aires Chair: Keith Hoots, U.S.A. n A Role for Prophylaxis <strong>in</strong> Inhibitor Patients? Keith Hoots, U.S.A. n Update on Immune Tolerance Elena Santagost<strong>in</strong>o, Italy n Differential Responses to Bypass<strong>in</strong>g Agents Jan Astermark, Sweden W1.2 - MUSCULOSKELETAL Therapeutic Exercise Tool Box Room: Palermo Co-Chairs: Greig Blamey, Canada, and Thuvia Flannery, U.K. n Function Piet de Kleijn, the Netherlands n Strength Nick Zourikian, Canada 34 n Flexibility Angela Forsyth, U.S.A. n Proprioception Lee Short, U.K. n Balance Natasha Jankovic, Serbia W1.3 - MULTIDISCIPLINARY ≤ Meet the Real Experts: Life Stages Room: Belgrano Chair: Bel<strong>in</strong>da Burnett, New Zealand n Youth Perspective from a Develop<strong>in</strong>g Country Vaibhav Nehra, India n Youth Perspective from a Developed Country Paul Wilton, Canada n Middle-Age Perspective from a Developed Country Gabriele Callizani, Italy n Middle-Age Perspective from a Develop<strong>in</strong>g Country Yuri Zhulyov, Russia n Older Perspective from a Developed Country Gordon Clarke, U.K. n Older Perspective from a Develop<strong>in</strong>g Country Said Ul-Islam, Pakistan W1.4 - MEDICAL Free Papers IV Room: Ceibo (1st floor) Co-Chairs: Angelika Batorova, Slovakia, and Wolfhart Kreuz, Germany n Platelet B<strong>in</strong>d<strong>in</strong>g of NN1731, a Factor VIIa Variant with Enhanced Tissue Factor- Independent Activity Hoffman M1 , Persson E2 , Ezban M2 , Monroe DM3 1Duke University & Durham Veterans Affairs Medical Center, Durham, North Carol<strong>in</strong>a U.S.A.; 2 3 Novo Nordisk A/S, Måløv, Denmark; University of North Carol<strong>in</strong>a, Chapel Hill, North Carol<strong>in</strong>a, U.S.A.
Congress Sessions cont’d n Inhibitor Incidence <strong>in</strong> Hemophilia A Patients Intensively Treated with Cont<strong>in</strong>uous Infusion of Factor VIII Batorova A1 , Holme P2 , Gr<strong>in</strong>geri A3 , Fijnvandraat K4 , Richards M5 , Hermans C6 , Altisent C7 , Lopez- Fernández M8 on behalf of the European Hemophilia Treatment Standardization Board (EHTSB) 1National Hemophilia Center, Dept. of Hematology and Transfusion Medic<strong>in</strong>e, University Hospital, Bratislava, Slovakia, 2Haematology Medical Department, Rikshospitalet, University Hospital, Oslo, Norway, 3Centro Emofilia A. Bianchi Bonomi, University Hospital, Milan, Italy, 4Department of Pediatric Hematology, Academic Medical Center, Amsterdam, the Netherlands, 5Paediatric Haematology Department, Children’s Day Hospital, St. James University Hospital, Leeds, United K<strong>in</strong>gdom, 6Haemostasis Department, Cl<strong>in</strong>iques Universitaires St Luc, Bruxelles, Belgium, 7Servicio de Hematologia – Unidad de Hemofilia, Hospital Val d’ Hebron, Barcelona, 8Thrombosis and Haemostasis Unit. Servicio de Hematología y Hemoterapia, Complexo Hospitalario Universitario de A Coruña, Coruña, Spa<strong>in</strong> n Factor VIII Light Cha<strong>in</strong> Mutations and Cyste<strong>in</strong>e Substitutions Predispose for Inhibitor Development <strong>in</strong> Mild and Moderate Hemophilia A: First Results From the INSIGHT Study Eckhardt CL1 , 2 , Peters M1 , Kamphuisen PW2 , Astermark J3 , Oldenburg J4 , Hay CRM5 , Santagost<strong>in</strong>o E6 , Ingerslev J7 , D’Oiron R8 , van der Bom JG9 and Fijnvandraat K1 for the INSIGHT <strong>in</strong>vestigators 1Paediatric Haematology, Emma Children’s Hospital, Amsterdam, the Netherlands, 2Vascular Medic<strong>in</strong>e, Academic Medical Center, Amsterdam, the Netherlands, 3Centre for Thrombosis and Haemostasis, Malmö University Hospital, Lund University, Malmö, Sweden, 4Institute of Experimental Haematology and Transfusion Medic<strong>in</strong>e, University Hospital Bonn, Bonn, Germany, 5Hemophilia Center, Manchester Royal Infirmary, Manchester, U.K., 6Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital, Mangiagalli & Reg<strong>in</strong>a Elena Foundation, University of Milan, Milan, Italy, 7University Hospital Skejby, Aarhus, Denmark, 8Haemophilia Centre, Hôpital Bicêtre, Paris, France, 9Cl<strong>in</strong>ical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands n Inhibitor Incidence <strong>in</strong> Previously Untreated Patients (PUPs) with Hemophilia A and B - <strong>F<strong>in</strong>al</strong> Evaluation of the Prospective PUP Study Conducted by the Paediatric Committee of the GTH (German, Swiss, and Austrian Society of Thrombosis and Haemostasis Research) Kreuz W1 , Auerswald G2 , Budde U3 , Lenk H4 , Escuriola Ett<strong>in</strong>gshausen C1, on behalf of GTH- PUP-Study-Group 1JW Goethe University Hospital, Dept. Pediatrics III, Frankfurt, 2ZKH St.Jürgen-Straße, Prof. Hess Childrens Hospital, Bremen, 3AescuLaboratory, Hamburg, 4University Hospital Leipzig, Dept. Pediatrics, Germany n First Human Dose Trial of Subcutaneously Adm<strong>in</strong>istered Recomb<strong>in</strong>ant Activated Factor VII (rFVIIa) to Hemophilia A and B Patients Shows Prolonged FVIIa Half-Life, and Provides Evidence of Safety and Tolerability Tiede A1 , Lethagen S2 , Friedrich U3 , Stenmo C3 , Allen G4 , Giangrande P5 , Goudemand J6 , Hay C7 , Holmström M8 , Klamroth R9 , McKenzie S10 , Miesbach W11 , Negrier C12 , Jimenez Yuste V13 and Berntorp E14 1Hannover Medical School, Hannover, Germany, 2 3 Rigshospitalet, Copenhagen, Denmark, Novo Nordisk A/S, Bagsvaerd, Denmark, 4Children’s Memorial Hospital, Chicago, U.S.A., 5Churchill Hospital, Oxford, U.K., 6Hôpital Cardiologique, Lille Cedex, France, 7Manchester Royal Infirmary, Manchester, U.K., 8Karol<strong>in</strong>ska Universitetssjukhuset, Stockholm, Sweden, 9Vivantes Kl<strong>in</strong>ikum im Friedrichsha<strong>in</strong>, Berl<strong>in</strong>, Germany, 10Thomas Jefferson University, Philadelphia, U.S.A., 11Institut für Transfusionsmediz<strong>in</strong> Universitätskl<strong>in</strong>ikum Frankfurt, Germany, 12Hôpital Edouard Herriot, Lyon, France, 13Hospital Universitario La Paz, Madrid, Spa<strong>in</strong>, 14Universitetssjukhuset MAS, Malmö, Sweden n Why Is the Frequency of Inhibitors Increas<strong>in</strong>g Among Swedish Children with Severe Hemophilia A? Ljung R1 , Petr<strong>in</strong>i P2 , Holmberg F1 1Lund University, Departments of Paediatrics and Malmö Centre for Thrombosis and Haemostasis, University Hospital, Malmö, Sweden and 2Paediatric Department of Coagulation Disorders, Karol<strong>in</strong>ska University Hospital, Stockholm, Sweden 35 Wednesday, July 14. 2010
Change language